Total Funding
73
53
Total FundingPost-IPO Equity raised
Growth Score
-1 pts
Heat Score
-7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
7296
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Ryan Cohlhepp: President & Chief Operating Officer- David Raben: Chief Medical Officer
Biocon
About the Company
Bicara Therapeutics is a clinical-stage biotechnology startup focused on developing dual-action biologics. The business is developing bifunctional antibodies that are designed to deliver an immunomodulatory payload directly to the tumor microenvironment, assisting cancer patients in increasing immune cell activity and potentially providing
long-term efficacy.
